Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses the role of SERDs in the treatment landscape of ER-positive breast cancer. Whilst they have demonstrated limited benefit in ESR1 wild type breast cancer, findings from the EMERALD trial (NCT03778931) of elacestrant and the AMEERA-3 trial (NCT04059484) have demonstrated benefit in ESR1-mutant breast cancer. These trials have highlighted the need for better patient selection and SERDs may additionally prove to be beneficial in combination regimens, with the Phase III evERA trial (NCT05306340) assessing giredestrant with everolimus in patients with ER-positive, HER2-negative breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть